February 2024 SOCRA Source Journal - Journal - Page 60
REFERENCES
30. McKenna K, Geoghegan C, Swezey T, et al. Investigator experiences using mobile technologies in
clinical research: qualitative descriptive study. JMIR Mhealth Uhealth. 2021;9(2):e19242.
31. Unger J, Gralow J, Albain K, et al. Patient income level and cancer clinical trial participation. JAMA
Network. 2016;2(1):137–139. doi:10.1001/jamaoncol.2015.3924
32. Income, poverty and health insurance coverage in the United States: 2010. United States Census
Bureau. https://www.census.gov/newsroom/releases/archives/income_wealth/cb11-157.html#tablea.
Published September 13, 2011. Accessed April 18, 2022.
33. Waddington D. Census Bureau statistics measure equity gaps across demographic groups. United States
Census Bureau. https://www.census.gov/library/stories/2021/09/understanding-equity-through-censusbureau-data.html. Published September 14, 2021. Accessed April 18, 2022.
34. Muvuka B, Combs R, Ayangeakaa S, et al. Health literacy in African American communities: barriers and
strategies. Health Literacy Research and Practice. 2020;4(3):138–143. doi:10.3928/24748307-20200617-01
35. US Census Bureau releases new educational attainment data. United States Census Bureau. https://
www.census.gov/newsroom/press-releases/2020/educational-attainment.html. Published March 30, 2020.
Accessed April 18, 2022.
36. Malik L and Mejia A. Informed consent for phase I oncology trials: form, substance and signature.
Journal of Clinical Medicine Research. 2014;6(3):205–208. doi:10.14740/jocmr1803w
37. Bleiberg H, Decoster G, Gramont A, et al. A need to simplify informed consent documents in cancer
clinical trials. A position paper of the ARCAD group. Annals of Oncology. 2017;28(5):922–930. doi:10.1093/
annonc/mdx050
38. Sharrocks K, Spicer J, Camidge DR, et al. Br J Cancer. 2014;111(9):1684–1687. doi:10.1038/
bjc/2014/108
39. Galsky M, Stensland K, McBride R, et al. Geographic accessibility to clinical trials for advanced
cancer in the United States. JAMA Intern Med. 2015;175(2):293–295. https://jamanetwork.com/journals/
jamainternalmedicine/fullarticle/1936578.
40. South census region. Census Bureau. https://www.bls.gov/regions/southeast/south.htm. Accessed July
2, 2022.
41. South Carolina black population percentage by county. Index Mundi. Accessed April 8, 2022. https://
www.indexmundi.com/facts/united-states/quick-facts/south-carolina/black-population-percentage#map.
42. South Carolina clinical trials. Wcg Center Watch. Accessed April 8, 2022. https://www.centerwatch.com/
clinical-trials/listings/location/united-states/SC/.
43. Fulvestrant plus Enzalutamide in ER+/Her2- advanced breast cancer. Accessed May 22, 2022. https://
www.clinicaltrials.gov/ct2/show/study/NCT02953860.
44. Effect of Triptorelin (Decapeptyl) 22.5mg on two biomarkers in patients with advanced prostate cancer
(Triptocre). Accessed May 22, 2022. https://www.clinicaltrials.gov/ct2/show/study/NCT01020448.
45. Single dose intravesical Apaziquone postoperative in patients undergoing TURBT for noninvasive
bladder cancer. Accessed May 22, 2022. https://www.clinicaltrials.gov/ct2/show/study/NCT00598806.
46. PD-L1 inhibition as checkpoint immunotherapy for neuroendocrine phenotype prostate cancer. Accessed
May 22, 2022. https://www.clinicaltrials.gov/ct2/show/study/NCT03179410.
doi:10.3928/24748307-20200617-01
47. Temsirolimus with or without megestrol acetate and tamoxifen citrate in treating patients with advanced,
persistent, or recurrent endometrial cancer. Accessed May 22, 2022. https://www.clinicaltrials.gov/ct2/show/
results/NCT00729586.
48. A phase II study of Nivolumab in combination with Cabozantinib for metastatic triple-negative breast
cancer. Accessed April 8, 2022. https://www.clinicaltrials.gov/ct2/show/results/NCT03316586.
49. Chemotherapy, radiation therapy, and surgery in treating patients with locally advanced cancer of the
vulva. Accessed May 22, 2022. https://www.clinicaltrials.gov/ct2/show/results/NCT00068406.
50. Bevacizumab and intravenous or intraperitoneal chemotherapy in treating patients with stage II–III
ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Accessed May 22, 2022.https://
www.clinicaltrials.gov/ct2/show/results/NCT00951496.
60
SOCRA SOURCE © May 2023